An integrated genomic approach to identify predictive biomarkers of response to the Aurora kinase inhibitor PF-03814735
Menée sur 87 lignées cellulaires de divers types de cancer et à l'aide de xénogreffes, cette étude suggère qu'un biomarqueur basé sur l'expression de la famille des gènes Myc permet de prédire la réponse à un traitement à l'aide d'un composé appelé PF-03814735, un inhibiteur des kinases Aurora A et B
PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment of advanced solid tumors. To find predictive biomarkers, we screened a diverse panel of 87 cancer cell lines for growth inhibition upon PF-03814735 treatment. Small cell lung cancer (SCLC) and to a lesser extent colon cancer lines were very sensitive to PF-03814735. The status of the Myc gene family and retinoblastoma pathway members significantly correlated with the efficacy of PF-03814735. While RB1 inactivation, intact CDKN2A/p16, and normal CCND1/Cyclin D1 status are hallmarks of SCLC, activation or amplification of any of the three Myc genes (MYC, MYCL1, MYCN) clearly differentiated cell line sensitivity within the SCLC panel. By contrast, we found that expression of Aurora A and B were weak predictors of response. We observed a decrease in histone H3 phosphorylation and polyploidization of sensitive lines, consistent with the phenotype of Aurora B inhibition. In vivo experiments with two SCLC xenograft models confirmed the sensitivity of Myc genes driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc driven tumors. Altogether our results suggest that SCLC and other malignancies driven by the Myc family genes may be suitable indications for treatment by Aurora B kinase inhibitors.
Molecular Cancer Therapeutics , résumé, 2012